Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
Latest in diagnostics in EGFR mutated NSCLC
Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA
Latest in diagnostics in EGFR mutated NSCLC ( Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA )
3 Dec 2021
WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht...
WCLC 2021: Epidemiology of MET Exon 14 mutations ( Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger )
19 Oct 2021
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )
11 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )
6 Oct 2021
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant...
Dr Pascale Tomasini and Dr Catherine Shu
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )
27 Sep 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...
Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation